全文获取类型
收费全文 | 82669篇 |
免费 | 8325篇 |
国内免费 | 200篇 |
学科分类
医药卫生 | 91194篇 |
出版年
2021年 | 1115篇 |
2020年 | 738篇 |
2019年 | 1122篇 |
2018年 | 1400篇 |
2017年 | 1006篇 |
2016年 | 1101篇 |
2015年 | 1251篇 |
2014年 | 1645篇 |
2013年 | 2585篇 |
2012年 | 3473篇 |
2011年 | 3753篇 |
2010年 | 1999篇 |
2009年 | 1924篇 |
2008年 | 3229篇 |
2007年 | 3575篇 |
2006年 | 3425篇 |
2005年 | 3482篇 |
2004年 | 3249篇 |
2003年 | 3022篇 |
2002年 | 2963篇 |
2001年 | 2716篇 |
2000年 | 2831篇 |
1999年 | 2512篇 |
1998年 | 1105篇 |
1997年 | 922篇 |
1996年 | 914篇 |
1995年 | 817篇 |
1994年 | 832篇 |
1993年 | 758篇 |
1992年 | 2085篇 |
1991年 | 2025篇 |
1990年 | 1896篇 |
1989年 | 1862篇 |
1988年 | 1784篇 |
1987年 | 1791篇 |
1986年 | 1687篇 |
1985年 | 1673篇 |
1984年 | 1386篇 |
1983年 | 1252篇 |
1982年 | 842篇 |
1981年 | 717篇 |
1980年 | 639篇 |
1979年 | 1209篇 |
1978年 | 871篇 |
1977年 | 764篇 |
1976年 | 712篇 |
1975年 | 714篇 |
1974年 | 859篇 |
1973年 | 751篇 |
1972年 | 732篇 |
排序方式: 共有10000条查询结果,搜索用时 468 毫秒
21.
James R. Barrett MD Victoria Rendell MD Courtney Pokrzywa MD Alexandra G. Lopez-Aguiar MD John Cannon BA George A. Poultsides MD MS Flavio Rocha MD Angelena Crown MD Eliza Beal MD Timothy Michael Pawlik MD MPH PhD Ryan Fields MD Roheena Z. Panni MD MPHS Paula Smith MD Kamran Idrees MD Clifford Cho MD Megan Beems MD Shishir Maithel MD Sharon Weber MD Daniel Erik Abbott MD 《Journal of surgical oncology》2020,121(7):1067-1073
22.
A. Nast C. Smith P.I. Spuls G. Avila Valle Z. Bata-Csörgö H. Boonen E. De Jong I. Garcia-Doval P. Gisondi D. Kaur-Knudsen S. Mahil T. Mälkönen J.T. Maul S. Mburu U. Mrowietz K. Reich E. Remenyik K.M. Rønholt P.G. Sator M. Schmitt-Egenolf M. Sikora K. Strömer O. Sundnes D. Trigos G. Van Der Kraaij N. Yawalkar C. Dressler 《Journal of the European Academy of Dermatology and Venereology》2020,34(11):2461-2498
This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab. 相似文献
23.
24.
James I. Geller MD Joseph G. Pressey MD Malcolm A. Smith MD Rachel A. Kudgus PhD Mariana Cajaiba MD Joel M. Reid PhD David Hall PhD Donald A. Barkauskas PhD Stephen D. Voss MD Steve Y. Cho MD Stacey L. Berg MD Jeffrey S. Dome MD PhD Elizabeth Fox MD Brenda J. Weigel MD 《Cancer》2020,126(24):5303-5310
25.
Béla Nagy Zsolt Bene Zsolt Fejes Sonya L. Heltshe David Reid Nicola J. Ronan Yvonne McCarthy Daniel Smith Attila Nagy Elizabeth Joseloff György Balla János Kappelmayer Milan Macek Scott C. Bell Barry J. Plant Margarida D. Amaral István Balogh 《Journal of cystic fibrosis》2019,18(2):271-277
Background
We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.Methods
In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).Results
After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).Conclusions
This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. 相似文献26.
27.
Pretibial lacerations and lower limb wounds are referred to plastic surgery teams for split skin graft surgery. Traditionally, these patients have been immobilised on bedrest following surgery. More recently, patients have commenced ambulation earlier to avoid medical complications and facilitate discharge. The objective of this literature review was to determine when such patients should begin walking. A literature search was undertaken using the electronic databases AMED, Cinahl, Embase, Medline (via Ovid), PEDro and Pubmed. Clinical trials using human subjects, written in English, were included. Seventeen (of 1137) papers met the inclusion criteria and were reviewed. The literature suggested that patients should begin walking immediately or at the earliest possible opportunity after lower limb skin graft surgery. Although the literature advocated early ambulation, the evidence base presented with a number of recurrent methodological limitations, including small sample sizes, lack of a control sample, and limited follow-up. Accordingly, further research employing large, well-designed, randomised controlled trials is recommended. It will then be possible to understand with greater certainty when patients should begin walking after lower extremity split skin graft surgery. 相似文献
28.
29.
Stacey A Thom Jeannette D Hoit Thomas J Hixon Alice E Smith 《The Cleft palate-craniofacial journal》2006,43(5):539-546
OBJECTIVE: To determine the age at which infants achieve velopharyngeal closure during vocalization. DESIGN: Longitudinal with repeated measures. SETTING: Laboratory. PARTICIPANTS: Six healthy infants were studied monthly from ages 2 to 6 months while they interacted with a parent and an investigator. MAIN OUTCOME MEASURES: The presence or absence of velopharyngeal closure, as determined by sensing ram pressure at the anterior nares. RESULTS: The velopharynx was open for windups, whimpers, and laughs, and it was closed for cries, screams, and raspberries, regardless of age. The frequency with which the velopharynx closed during syllable utterances increased significantly with age. CONCLUSIONS: Velopharyngeal closure for speech-like utterance increases with age, but is not complete and is still undergoing development at 6 months of age. Velopharyngeal closure during infancy may be influenced by pressure demands of the utterance; however, support for this speculation is stronger for other types of utterances than it is for speech-like utterances. The method used in this study holds promise for evaluating infants with suspected velopharyngeal impairment. 相似文献
30.
H. Newell J. D. Smith P. Rogers E. Birks A. J. Danskine R. E. Fawson M. L. Rose 《American journal of transplantation》2006,6(7):1712-1717
Implantation of left ventricular assist devices (LVAD) is associated with HLA antibody sensitization. The objective of this study was to determine the specificity of antibodies produced by LVAD recipients using a combination of ELISA, Luminex and microcytotoxicity assays. Fifty-one LVAD patients were studied, from 44 to 838 days post-implantation. No patient developed HLA antibodies, although 24 produced IgG antibodies detectable in both ELISA and Luminex assays. These antibodies manifest as positive reactions with class I and class II wells of the ELISA and also blank wells. In Luminex assays, they produce high MFI readings with the negative control beads. Antibodies were detected 18 to 228 days after implantation. This reactivity was found to be directed against bovine serum albumin (BSA), commonly used to block non-specific binding in ELISA and Luminex assays; absorption of sera with BSA-coated beads completely abrogated reactivity in all solid phase assays, but did not eliminate anti-HLA antibodies in control sera. Ten of the 24 patients have proceeded to transplantation, with a 1-year graft survival of 69%. In conclusion, it appears that implantation of LVADS disrupts immunoregulatory pathways leading to production of anti-albumin antibodies. These can be misinterpreted as anti-HLA antibodies in solid phase assays. 相似文献